Method Of Use Patents Gaining Greater Importance In The Eyes Of Pharma
Executive Summary
Large pharmaceutical manufacturers are beginning to see method of use patents as a more valuable piece of their patent portfolios, Gene Logic CEO Mark Gessler said at the Biotechnology Industry Organization/Windhover Partnering Conference for Decision Makers in Washington, D.C. May 17
You may also be interested in...
FDA Developing Brand/Generic Labeling “Carve Out” Notification Process
FDA is developing a process to inform innovators and generic companies when part of a brand drug's labeling can be "carved out" of an ANDA, Associate Counsel for Drugs Elizabeth Dickinson said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials